Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.

Slides:



Advertisements
Similar presentations
Is this the “spioenkop” for CABG?
Advertisements

Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy Educational Fellowship in PCI.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
Optimal Medical Therapy with or without Coronary Artery Bypass Graft for Stable Triple Vessel Coronary Artery Disease Ray P. Aswat, M.D. Adult Cardiology.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
PCI VS CABG JOURNAL REVIEW
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association.
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
Ischemic heart disease. Indications and methods of surgical treatment. Surgery department №2.
New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.
New guidelines for CABG
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.
Multivessel Coronary Artery Disease
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Multivessel PCI in an Era of Freedom and FAME Michael J. Cowley, MD, FSCAI Nothing to Disclose.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Clinical Results Following Stenting of.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Choosing Wisely: Cardiology Jeffrey Ziffra D.O. Mercy Medical Center – North Iowa 10/14/2016.
S Ten Tse and Sensibility!
From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.
Figure 1 A flow chart describing the systematic process followed for article selection.  From: A systematic review of cost-effectiveness of percutaneous.
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Glenn N. Levine et al. JACC 2016;68:
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Peter K. Smith, MD  The Annals of Thoracic Surgery 
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Maintenance of Long-Term Clinical Benefit with
To bypass or stent? The changing rules of an advancing game
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Glenn N. Levine et al. JACC 2011;58:e44-e122
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Davide Capodanno et al. JCIN 2009;2:
Transatlantic editorial: A comparison between European and North American guidelines on myocardial revascularization  Philippe Kolh, MD, PhD, Paul Kurlansky,
The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization  Lorenzo Azzalini,
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II

Definitions Recommendations for revascularization in the setting of symptomatic, stable ischemic heart disease; does not include revascularization in the setting of acute MI Significant Stenosis: – Left Main Disease – Fractional Flow Reserve “Protected” vs “Unprotected” LM disease STS Score/SYNTAX score

STS Score

SYNTAX Score

Approach Considerations Class I – Heart Team Approach Class IIa – STS/SYNTAX Scores

Left Main Disease Class I – CABG for LMD ≥ 50% Class IIa – PCI is reasonable in: SYNTAX ≤ 22 & STS Mortality ≥ 5% UA/NSTEMI with unprotected LM & not CABG candidate STEMI with unprotected LM as the culprit lesion with TIMI 3 flow and time constraints Class IIb – PCI may be reasonable in: SYNTAX 2%, previous surgery, mod-severe COPD

Non-LM Disease Class I – CABG for significant 3VD (w w/o prox LAD) or prox LAD + 1 other major coronary artery – CABG or PCI for SCD 2/2 significant stenosis (PCI LOE C) Class IIa – CABG for significant 2VD with extensive myocardial ischemia or target vessels supply large area of viable myocardium – CABG for significant MVD or Prox LAD w/ mild-moderate LV systolic dysfunction w/ viable myocardium – CABG w/ LIMA for significant proximal LAD and extensive ischemia – CABG > PCI w/ SYNTAX > 22 if good candidates – CABG probably recommended > PCI with DM and MVD

Non-LM Disease Cont’d Class IIb – CABG uncertain w/ 2VD (w/o prox LAD) and w/o extensive ischemia – PCI to improve survival uncertain in 2VD/3VD (w/ w/o prox LAD) or isolated prox LAD disease – CABG for sole intent of survival benefit in SIHD w/ EF < 35% regardless of viable myocardium – CABG or PCI uncertain w/ previous CABG and extensive anterior wall ischemia

Symptom Relief Class I – CABG/PCI is beneficial w/ ≥ 1 significant lesions amenable to revascularization and unacceptable angina w/ GDMT Class IIa – CABG/PCI for above when GDMT can’t be implemented – PCI reasonable in previous CABG w/ 1 or more significant lesions – CABG reasonable w/ SYNTAX > 22 and good candidate Class IIb – CABG might be reasonable w/ previous CABG and 1 or more significant lesions not amenable to PCI – Transmyocardial laser revascularization for non-graftable vessels

CABG vs MT 3 RCTs in 1970s and 80s show CABG > Medical therapy – VA Cooperative Study – European Coronary Surgery Study – Coronary Artery Surgery Study (CASS) 1994 Meta-analysis showed CABG > MT in LM/3VD CABG > MT for angina Medicine, Angioplasty, or Surgery Study II (MASS II) in early 2000s; CABG with less subsequent MI, revascularization, cardiac death at 10 years

PCI vs MT Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) & Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) No survival advantage for PCI PCI reduces angina PCI may increase short-term risk of MI PCI does not reduce long-term risk of MI

References 1.L. David Hillis et. Al, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 2011; Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645–53. 3.White AJ, Kedia G, Mirocha JM, et al. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. J Am Coll Cardiol Intv. 2008;1:236–45. 4.Makikallio TH, Niemela M, Kervinen K, et al. Coronary angioplasty in drug eluting stent era for the treatment of unprotected left main stenosis compared to coronary artery bypass grafting. Ann Med. 2008;40: 437–43.